Dateline City:
KENILWORTH, N.J.
First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study
New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma
First-Time Findings in Multiple Myeloma and ER-Positive/HER2-Negative Breast Cancer as Well as New Findings in Classical Hodgkin Lymphoma
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that data investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in advanced non-small
cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple
myeloma, and ER-positive/HER2-negative breast cancer will be presented
at four medical congresses through the end of this year.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more